Anika Therapeutics
ANIK
191 hedge funds and large institutions have $708M invested in Anika Therapeutics in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 75 increasing their positions, 68 reducing their positions, and 20 closing their positions.
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
10% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 68
2% less funds holding
Funds holding: 194 → 191 (-3)
4.94% less ownership
Funds ownership: 100.66% → 95.72% (-4.9%)
7% less capital invested
Capital invested by funds: $761M → $708M (-$53.2M)
93% less call options, than puts
Call options by funds: $1.24M | Put options by funds: $17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$8.06M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$7.26M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.49M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.39M |
| 5 |
Renaissance Technologies
New York
|
+$5.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$10.8M |
| 2 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$8.82M |
| 3 |
Millennium Management
New York
|
-$5.57M |
| 4 |
D.E. Shaw & Co
New York
|
-$5.11M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.93M |
ANIK Hedge Fund Activity: Q4 2019 in Review
191 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2019, worth a combined $708M — down 7% from $761M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ANIK positions and 20 closed out — a net gain of 3 holders — while 75 added to existing stakes and 68 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $8.06M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $10.8M sold.
- 191 institutional investors held Anika Therapeutics (ANIK) as of Q4 2019, down from 194 in Q3 2019.
- Funds reported $708M of Anika Therapeutics stock for Q4 2019, down 7% quarter-over-quarter.
- 23 funds opened new Anika Therapeutics positions in Q4 2019 and 20 closed out, a net change of +3 holders.
- The largest Anika Therapeutics buyer in Q4 2019 was Goldman Sachs, an estimated $8.06M added.
- The largest Anika Therapeutics seller in Q4 2019 was Acadian Asset Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q4 2019.